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Abstract
Purpose: To evaluate safety and efficacy of the vascular endothelial growth factor binding protein abicipar
pegol (abicipar) versus ranibizumab for neovascular age-related macular degeneration.
Methods: Phase 2, multicenter, randomized, double-masked comparison (REACH study, stage 3). Patients
(n= 64) received intravitreal injections of abicipar 1mg or 2mg at baseline, week 4, and week 8 (3 injections) or
ranibizumab 0.5mg at baseline and monthly (5 injections).
Results: In the abicipar 1mg (n= 25), abicipar 2mg (n= 23), and ranibizumab (n= 16) arms, respectively, least-
squares mean best-corrected visual acuity (BCVA) change from baseline was +6.2, +8.3, and +5.6 letters at
week 16 (primary endpoint) and +8.2, +10.0, and +5.3 letters at week 20. Least-squares mean central retinal
thickness (CRT) reduction from baseline was 134, 113, and 131mm at week 16 and 116, 103, and 138mm at
week 20. Intraocular inflammation adverse events (AEs), reported in 5/48 (10.4%) abicipar-treated patients,
resolved without sustained vision loss or other sequelae.
Conclusions: Abicipar demonstrated durability of effect: BCVA and CRT improvements were similar between
abicipar and ranibizumab at weeks 16 and 20 (8 and 12 weeks after the last abicipar injection and 4 weeks after
the last ranibizumab injection). No serious AEs were reported.
Keywords: abicipar pegol, age-related macular degeneration, anti-VEGF, choroidal neovascularization, optical
coherence tomography, vascular endothelial growth factor
Introduction
Age-related macular degeneration (AMD), char-acterized by progressive degeneration of photoreceptors
and retinal pigment epithelium (RPE), is the leading cause of
irreversible blindness in older individuals residing in devel-
oped countries.1 It is estimated that approximately 9 million
people in the United States had large drusen or advanced
stage AMD in 2000, and this number is projected to almost
double by the year 2020.2 The disease is typically classified
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as early AMD when medium drusen (‡63 to £125 mm) are
present and intermediate AMD when large drusen (>125mm),
or medium drusen associated with pigmented abnormalities,
are present.3 The advanced forms of AMD are characterized
by geographic atrophy or neovascularization.1,3 In neovas-
cular AMD (nAMD), newly formed immature blood vessels,
originating from the choroid, break through Bruch’s mem-
brane and extend below the RPE or invade the subretinal
space. Choroidal neovascularization (CNV) and fluid exu-
dation from the immature vessels are associated with tissue
disruption, subretinal disciform scar formation with subse-
quent atrophy of the adjacent neurosensory retina, and much
of the severe vision loss that occurs in patients with AMD.1
Characterization of the endothelial cell proliferative and
vascular permeability effects of vascular endothelial growth
factor (VEGF) led to the development of anti-VEGF treat-
ments for nAMD. The registration studies with the anti-VEGF
antibody fragment ranibizumab (Lucentis, Genentech, South
San Francisco, CA) demonstrated inhibition of CNV lesion
growth and exudation and improvement in best-corrected
visual acuity (BCVA) in the eyes of patients with nAMD
when ranibizumab was administered on a fixed monthly
treatment schedule.4,5 Retreatment criteria largely based on
BCVA and central retinal thickness (CRT) were adopted in
the PrONTO and SUSTAIN studies in an attempt to reduce
monthly intravitreal injection burden, while maintaining ef-
ficacy.6,7 Results from the 40-patient PrONTO study were
encouraging, with a mean BCVA improvement of 9.3 letters
in patients receiving an average of 5.6 intravitreal injections
over a 12-month period.6 In the 513-patient SUSTAIN study,
which had similar inclusion/exclusion criteria and baseline
lesion characteristics, the mean improvement in BCVA at
month 12 was only 3.6 letters, with an average of 5.6 in-
travitreal injections over the 12-month study.7 Similarly,
results from the HORIZON trial suggested that less frequent
ranibizumab treatment results in an incremental decline in
BCVA from that achieved with monthly treatment.8 These
studies emphasized the need for therapies that provide effi-
cacy equivalent to monthly intravitreal ranibizumab, but with
a reduced number of injections.
DARPin therapeutics (a registered trademark of Mole-
cular Partners AG, Switzerland; DARPin was originally de-
rived from designed ankyrin repeat protein) represent a novel
class of protein binding molecules under evaluation as po-
tential therapeutics for a number of indications in oncology
and ophthalmology, and for human immunodeficiency virus
and allergic reactions including allergic asthma.9–11 Abicipar
pegol (AGN-150998, MP0112, abicipar; Allergan plc/Molecular
Partners) is a member of this class of protein binding mole-
cules that specifically binds with high affinity to all soluble
isoforms of VEGF-A.12 Abicipar has a smaller molecular
weight (34 kDa vs. 48 kDa),12 higher target binding affinity
(2 pM vs. 46 pM),13,14 and longer ocular half-life (half-life of
‡13 days vs. 7 days in the aqueous humor) than ranibizu-
mab.13,15 These properties are believed to contribute to
greater durability of action compared with currently available
anti-VEGF therapies.
Abicipar was evaluated in a phase 2 study (REACH) in
patientswith nAMD.REACHwas conducted in 3 stages. Stage
1 evaluated the safety of abicipar after a single intravitreal
injection in patients with advanced nAMD (n= 24). Stage 2
assessed the safety and treatment effects of abicipar compared
with ranibizumab using as-needed administration in treatment-
naive nAMD patients (n= 183). Based on stage 1 and 2 out-
comes, stage 3 (n= 64) was designed to directly compare the
efficacy, safety, and systemic pharmacokinetic profile of 1-mg
and 2-mg injections of abicipar compared with ranibizumab
0.5mg for the treatment of nAMD. In addition, durability of
abicipar effects was assessed for potential dosing intervals of 8
and 12 weeks. REACH stage 3 is the focus of this article.
Methods
The phase 2 REACH stage 3 study was a 20-week,
multicenter, randomized, parallel-group, double-masked
comparison of the safety and treatment effects of repeat
abicipar and ranibizumab administration on BCVA and
retinal edema in treatment-naive patients with nAMD.
REACH stage 3 was conducted from September 29, 2011
to April 9, 2014. The REACH stage 3 protocol adhered to
the tenets of the Declaration of Helsinki and was ap-
proved by an institutional review board or ethics com-
mittee for each clinical site, and all participants provided
written informed consent. The REACH study is registered
with the identifier NCT01397409 at ClinicalTrials.gov.
Study population
Inclusion criteria included the presence of active CNV sec-
ondary to AMD in the study eye, defined as subfoveal or jux-
tafoveal lesions (within 200mm of the center of the foveal
avascular zone) with leakage affecting the fovea, as confirmed
by the central reading center (CRC; Bern Photographic Reading
Center, Bern, Switzerland). The CNV must have been diag-
nosed within the previous 12 months. BCVA in the study eye
was required to be between 75 and 24 letters (*20/32 and 20/
320 Snellen equivalent). Active CNV was defined by fluores-
cein leakage on fluorescein angiography and/or the presence of
retinal fluid within or below the retina or below the RPE, as
assessed with spectral-domain optical coherence tomography
(SD-OCT). The area of CNV within the lesion was required to
be >50% of the total lesion area and not larger than 12 disk
areas, as confirmed by the CRC. Inclusion was limited to pa-
tients who had not received any previously administered, ap-
proved or investigational therapy for nAMD in the study eye.
Key exclusion criteria included subretinal hemorrhage in
the study eye involving the center of the fovea with size either
>50% of the lesion area or >1 disk area; vitreous hemorrhage
in the study eye; history of rhegmatogenous retinal detach-
ment in the study eye; subfoveal fibrosis or scarring within
the lesion in the study eye, or retinal angiomatous prolifera-
tion lesion, or large (>50% of the CNV lesion) subfoveal
pigment epithelium detachment as confirmed by the CRC;
prior submacular surgery or vitrectomy in the study eye;
active infection or inflammation in either eye; and history of
chronic therapy with systemic or topical corticosteroids or
any intraocular therapy with corticosteroids within the past 6
months. If both eyes met the eligibility criteria, the eye with
the worst vision was selected as the study eye.
Randomization and intervention
Study visits were scheduled at baseline (day 1), day 3, and
weeks 1, 4, 8, 12, 16, and 20. At the baseline visit, enrolled
patients were randomized using a 3:3:2 ratio to intravitreal
administration of abicipar 1mg, abicipar 2mg, or ranibi-
zumab 0.5mg (0.05mL injection volume for each study
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drug). The assignment to treatment arms was based on order
of enrollment and a computer-generated randomization
schedule provided by the sponsor. Abicipar was provided in
phosphate-buffered saline at *60mg/mL, stored at -20C,
and diluted at the clinical trial sites to 20 and 40mg/mL for
the 1mg and 2mg doses. Ranibizumab 0.5mg was provided
at 10mg/mL for 0.5-mg doses. A schematic of the study
design is shown in Supplementary Fig. S1 (Supplementary
Data are available online at www.liebertpub.com/jop).
Patients randomized to the ranibizumab arm received 5
monthly intravitreal injections administered at the baseline
visit and at weeks 4, 8, 12, and 16. Patients randomized to
abicipar (1mg or 2mg) received 3 monthly intravitreal in-
jections administered at the baseline visit and at weeks 4 and
8. Because different storage conditions and dilutions of the
study drugs were needed, investigators who performed the
injections were unmasked to treatment. However, patients
were masked to their treatment assignment, and all efficacy
assessments were performed by study personnel who were
masked to patients’ treatment assignment. To maintain
masking, patients in the abicipar treatment arms received a
sham injection procedure at weeks 12 and 16.
At week 12 and later visits, patients could be treated with
standard of care (SoC) if there was evidence of any active
disease, as determined by the investigator. Evidence of ac-
tive disease included retinal fluid on OCT, or other signs of
active CNV including new or persistent subretinal or in-
traretinal hemorrhage, a decrease in visual acuity from the
last visit without another explanation, or leakage or an in-
crease in lesion size relative to the last angiogram on fluo-
rescein angiography. Patients were followed to week 20 or to
4 weeks after escape to SoC, whichever occurred earlier.
Outcome measures
Efficacy evaluations including BCVA and OCT imaging
were performed at all study visits except day 3 (safety visit).
BCVA was assessed using a modification of the Early
Treatment Diabetic Retinopathy Study (ETDRS) method.16
OCT measurements were performed with either a Cirrus
(Carl Zeiss Meditec, Jena, Germany) or a Spectralis (Hei-
delberg Engineering, Heidelberg, Germany) spectral-domain
instrument; all measurements for an individual patient were
performed with the same instrument. OCT images were
graded at the CRC for both CRT (average thickness in the 1-
mm diameter central macular subfield) and fluid compart-
ments by readers masked to the treatment assignment. Fluid
compartments were defined by the CRC as follows: subretinal
fluid (SRF), fluid between the photoreceptor layer and the
RPE; cystic intraretinal fluid (CIRF), a cavity within the
retina between the photoreceptor layer and the internal lim-
iting membrane; and non-cystic intraretinal fluid (NIRF),
diffuse thickening of the retina (‘‘spongiform’’ fluid) without
any visible CIRF or SRF. Fluorescein angiography was per-
formed at screening and week 20.
The primary endpoint was the mean change from baseline
in BCVA in the study eye at week 16. Key secondary effi-
cacy measures included mean change in BCVA from
baseline, mean change in CRT from baseline, and the pro-
portion of patients with ‡15-letter gain in BCVA from
baseline in the study eye at each scheduled follow-up visit.
The proportion of patients with stable vision (no loss or a
<15-letter loss in BCVA from baseline) in the study eye at
each scheduled follow-up visit was also evaluated. In ad-
dition, among patients who had at least 1 retinal fluid
compartment present at baseline in the study eye on OCT
(SRF, CIRF, or NIRF), the proportion who had no fluid
compartment present at follow-up (‘‘all dry’’ patients) was
a preplanned secondary endpoint at week 12 and was as-
sessed at each scheduled follow-up visit as an exploratory
endpoint.
Safety measures included adverse events (AEs), biomi-
croscopy and ophthalmoscopy, BCVA, assessment of the
study eye postinjection, physical examination, clinical lab-
oratory analysis (hematology, serum chemistry, and urinal-
ysis), and immunogenicity. AE reporting included the
seriousness and severity of the event, as well as the action
taken and the potential relationship to the study drug. Any
serious AE occurring during the study period (beginning
with informed consent) and for at least 28 days after the last
injection of study drug was to be immediately reported to
Allergan and followed up, with the outcome reported. AEs
were categorized by preferred terms using the Medical
Dictionary for Regulatory Activities (MedDRA) Version
16.1. For biomicroscopy/ophthalmoscopy findings with no
severity data collected, any finding that was reported as
absent at screening and present during the study was in-
cluded in the tabulation of findings with a 1+ increase in
severity.
Pharmacokinetic and immunogenicity analyses
Blood samples for pharmacokinetic analyses were col-
lected from patients at selected sites on day 1 (predose and
1 h postdose), day 3, and week 1, and predose at weeks 4, 8,
and 12. Serum abicipar concentrations were determined by
Charles River Laboratories (Montreal, Canada). In addition,
blood samples were collected from all patients on day 1 and
weeks 4, 12, and 20, before any administration of study
therapy, to assess immunogenicity. The presence of anti-
bodies directed against abicipar and the pegol moiety of
abicipar in samples collected from abicipar-treated patients
was evaluated by Charles River Laboratories using a vali-
dated enzyme-linked immunosorbent assay method. This
method involved an initial screening and confirmation of
positive samples with competitive binding assays using
abicipar or polyethylene glycol (PEG). Samples from pa-
tients before abicipar treatment were all negative for anti-
abicipar and anti-PEG antibodies. Immunogenicity results
were reported as positive or negative and are presented as
number and percentage of patients for each treatment arm.
Statistical analysis
Statistical analysis was performed using SAS version 9.3
software (SAS Institute, Inc., Cary, NC) and a 2-sided alpha
level of 0.05. Efficacy measures were evaluated in the
modified intent-to-treat (mITT) population of all random-
ized and treated patients with BCVA or CRT data at base-
line and at least 1 postbaseline timepoint. Safety measures
were evaluated in the safety population of all treated
patients.
Comparisons of baseline characteristics among treatment
arms used analysis of variance for age, Chi-square tests or
Fisher’s exact tests for sex and race, and the Cochran-
Mantel-Haenszel method with ridit scores for type of CNV.
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Study completion rates were compared among treatment
arms using the Chi-square test. Baseline BCVA and CRT
were compared among treatment arms using analysis of
variance with treatment and baseline BCVA strata (<55
letters or ‡55 letters) as factors. The statistical plan for the
study called for changes in BCVA and CRT from baseline to
be analyzed using analysis of covariance (ANCOVA)
models with baseline BCVA or CRT as the covariate. In
these preplanned analyses, any efficacy data collected after
escape to SoC in the abicipar arms were excluded from
analysis and set to missing, and missing values were im-
puted using the last-observation-carried-forward (LOCF)
method. Results of the preplanned analyses of change in
BCVA and CRT from baseline are provided in Supple-
mentary Tables S1 and S2.
Subsequently, post hoc efficacy analyses were conducted
using observed values with no imputation for missing val-
ues. The post hoc analyses also used more robust mixed
model repeated measures (MMRM) analysis of changes in
BCVA and CRT from baseline. Data collected from patients
in the ranibizumab arm after escape to SoC were included in
the analysis, because all of these patients received monthly
ranibizumab as the escape therapy. The results of the post hoc
analyses using observed values only and MMRM analysis of
changes in BCVA and CRT from baseline were consistent
with the results of the preplanned analyses using LOCF and
ANCOVA models of changes in BCVA and CRT from
baseline. All efficacy data presented in Results are from post
hoc analyses, with no imputation for missing values.
Changes in BCVA and CRT from baseline were analyzed
using an MMRM model that included treatment group,
baseline BCVA or CRT, visit, visit by baseline BCVA or
CRT interaction, and treatment by visit interaction as fixed
covariates in an unstructured covariance matrix. Statistically
significant differences between each abicipar arm and the
ranibizumab arm (abicipar arm minus ranibizumab arm)
were determined by calculating the 2-sided 95% confidence
intervals (CIs) of the differences and P values from the
MMRM model. The proportion of patients with ‡15-letter
BCVA gain, stable vision, and no fluid compartments on
OCT was analyzed at each visit using the Fisher’s exact test,
with a P value <0.05 considered statistically significant.
REACH stage 3 was not powered to detect statistically
significant differences in the primary endpoint. The planned
sample size of 64 patients, randomized in a 3:3:2 ratio to
abicipar 1mg, abicipar 2mg, and ranibizumab 0.5mg, was
determined empirically.
Results
Baseline characteristics and patient disposition
A total of 64 treatment-naive patients with nAMD were
enrolled at 15 sites in REACH stage 3 and were randomized
in a 3:3:2 ratio to study treatment. The mean age of the
patients was 76.6 years (range 53–91 years). Overall, 39/64
(61%) patients were female and 62/64 (97%) were white,
typical of an nAMD clinical study population. Baseline
patient characteristics were similar in the 3 treatment arms
(Table 1). There were no statistically significant differences
at baseline among the treatment arms in demographics or in
BCVA, CRT, or type of CNV in the study eye.
Study completion was defined as completion of the
week 20 visit or the visit 4 weeks after escape to SoC.
Overall, 62/64 (97%) patients completed REACH stage 3.
The study completion rate was comparable among treat-
ment arms (P = 0.159). Twenty-one (84.0%) patients in the
abicipar 1mg arm, 19 (82.6%) patients in the abicipar
2 mg arm, and 14 (87.5%) patients in the ranibizumab arm
completed the study at week 20; whereas 4 (16.0%) pa-
tients in the abicipar 1 mg arm, 2 (8.7%) patients in the
abicipar 2 mg arm, and 2 (12.5%) patients in the ranibi-
zumab arm completed the study at week 16, at 4 weeks
after escape to SoC. Two (8.7%) patients in the abicipar
2 mg arm discontinued REACH stage 3, one due to an AE.
The other patient withdrew consent because blood draws
were very uncomfortable for the patient. All randomized
patients received the assigned study treatment and were
included in the mITT, per-protocol, and safety populations
for analysis.
Table 1. Baseline Patient and Study Eye Characteristics in the REACH Stage 3 Study
Characteristic
Abicipar
1mg (n = 25)
Abicipar
2mg (n= 23)
Ranibizumab
0.5mg (n = 16)
P Value
Overall
Abicipar 1mg
vs. Ranibizumab
Abicipar 2mg
vs. Ranibizumab
Age, mean (SD), y 76 (10) 78 (6) 77 (9) 0.623
Gender 0.320
Female, n (%) 18 (72) 13 (57) 8 (50)
Race >0.999
White, n (%) 24 (96) 22 (96) 16 (100)
BCVA, mean (SD), ETDRS letters 58 (13) 59 (14) 60 (16) 0.996 0.488
CRT, mean (SD), mm 526 (165) 466 (126) 463 (95) 0.183 0.967
Type of CNV, n (%) 0.507 0.181
Predominantly classic 9 (36) 9 (39) 3 (19)
Occult (late leakage) 1 (4) 0 (0) 0 (0)
Occult (fibrovascular PED) 12 (48) 14 (61) 13 (81)
Occult with serous PED 0 (0) 0 (0) 0 (0)
Unable to grade 1 (4) 0 (0) 0 (0)
Other 2 (8) 0 (0) 0 (0)
PED, pigment epithelium detachment; SD, standard deviation.
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Escape treatment
During REACH stage 3, 14/25 (56.0%) patients treated
with abicipar 1mg, 11/23 (47.8%) patients treated with
abicipar 2mg, and 10/16 (62.5%) treated with ranibizumab
demonstrated active disease at or after week 12 and were
prescribed escape treatment. For patients in the abicipar
arms, efficacy data collected after escape treatment were
excluded from analysis; the number of patients in the abi-
cipar 1mg and 2mg arms included in the efficacy analyses
(i.e., had not escaped to SoC and did not have missing data)
was 24 (96%) and 22 (96%) at week 12, 19 (76%) and 19
(83%) at week 16, and 14 (56%) and 13 (57%) at week 20,
respectively.
Because the randomization schedule was uneven for ra-
nibizumab and all patients who met the criteria for escape in
the ranibizumab arm were prescribed monthly ranibizumab
as the escape therapy, efficacy data collected for patients in
the ranibizumab arm after escape were included in the pri-
mary analyses; the number of patients in the ranibizumab
arm included in the primary analyses presented was 16
(100%) at week 12, 16 (100%) at week 16, and 14 (88%) at
week 20. However, sensitivity analysis was conducted that
excluded all efficacy data from patients in all treatment arms
after escape to SoC (i.e., data collected after patients in the
ranibizumab arm escaped to SoC ranibizumab treatment
were also excluded from analysis). In the sensitivity anal-
ysis, the number of patients in the ranibizumab arm was 16
(100%) at week 12, 10 (62.5%) at week 16, and 7 (43.8%) at
week 20. Supplementary Fig. S2 shows the results of the
sensitivity analysis for each efficacy endpoint. Results of the
sensitivity analysis were confirmatory, and similar conclu-
sions were drawn from the primary and sensitivity analyses.
Efficacy outcomes
Improvements in BCVA were observed in all treatment
arms with no significant differences between the abicipar
and ranibizumab arms (Fig. 1). At week 16 (8 weeks after
the last abicipar and 4 weeks after the last ranibizumab
intravitreal administration), the least-squares (LS) mean
change in BCVA from baseline was +6.2, +8.3, and +5.6
letters in the abicipar 1mg, abicipar 2mg, and ranibizumab
0.5mg arms, respectively. At week 20 (12 weeks after the
last injection of abicipar and 4 weeks after the last in-
travitreal injection of ranibizumab), the LS mean change in
BCVA from baseline was +8.2, +10.0, and +5.3 letters in the
abicipar 1mg, abicipar 2mg, and ranibizumab 0.5mg arms,
respectively (Fig. 1). Summary statistics for the observed
data are provided in Supplementary Table S3.
Achievement of 3-line gains in vision and achievement of
stable vision were also comparable between the abicipar and
ranibizumab arms. The proportion of patients gaining 15
letters of vision in BCVA among those who remained in
REACH stage 3 and had not been rescued (unless rescued
with ranibizumab in the ranibizumab group) was 10.5%,
15.8%, and 12.5% in the abicipar 1mg, abicipar 2mg, and
ranibizumab 0.5mg arms, respectively, at week 16 (Fig. 2).
These BCVA gains at week 16 were achieved 8 weeks after
the last abicipar injection and 4 weeks after the last rani-
bizumab injection. At week 20, 12 weeks after the last
abicipar 1mg and 2mg injections and 4 weeks after the last
ranibizumab injection, the proportion of patients achieving
FIG. 1. Change in BCVA (letters) from baseline in the
modified intent-to-treat population of patients treated with
abicipar 1mg (light green lines and squares; n= 25), abicipar
2mg (dark green lines and squares; n= 23), or ranibizumab
0.5mg (orange lines and circles; n= 16). Data shown are
least-squares means– standard errors from the mixed-effects
model for repeated measures. There were no statistically
significant differences between abicipar 1mg or 2mg and
ranibizumab 0.5mg in change in BCVA from baseline. Green
and orange arrows indicate when the 3 abicipar injections or
5 ranibizumab injections were administered. Mean– standard
error of the mean BCVA at baseline for the abicipar 1mg,
abicipar 2mg, and ranibizumab 0.5mg arms was 58.4– 3.7,
58.5– 3.8, and 60.4– 4.1 letters, respectively. B, baseline.
BCVA, best-corrected visual acuity.
FIG. 2. Proportion (%) of patients in the modified intent-
to-treat population gaining ‡15 letters of best-corrected vi-
sual acuity from baseline after treatment with abicipar 1mg
(light green bars; n= 25), abicipar 2mg (dark green bars;
n = 23), or ranibizumab 0.5mg (orange bars; n = 16). Pro-
portions are calculated for patients with data available who
had not been rescued (unless rescued with ranibizumab in
the ranibizumab group). There were no statistically signifi-
cant differences between treatment arms. Green and orange
arrows indicate when the 3 abicipar injections or 5 ranibi-
zumab injections were administered.
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‡15-letter gain was 14.3%, 15.4%, and 14.3%, respectively
(Fig. 2). The proportion of patients with stable vision, de-
fined as no loss or a <15-letter loss in BCVA from baseline,
was also evaluated, as this was the primary endpoint in the
registration studies for ranibizumab and aflibercept in
nAMD.4,5,17 At week 16, the proportion of patients with
stable vision among those who remained in REACH stage 3
and had not been rescued (unless rescued with ranibizumab
in the ranibizumab group) was 100% in the abicipar 1mg
and 2mg arms and 93.8% in the ranibizumab 0.5mg arm. At
week 20, the proportion was 100% in all 3 treatment arms.
In REACH stage 3, abicipar 1mg and 2mg were similarly
effective compared with ranibizumab in reducing the ana-
tomical endpoint of CRT. The LS mean CRT reduction from
baseline was 134, 113, and 131mm at week 16 and 116, 103,
and 138mm at week 20 in the abicipar 1mg, abicipar 2mg,
and ranibizumab 0.5mg arms, respectively (Fig. 3). Sum-
mary statistics for the observed data are provided in Sup-
plementary Table S3. The proportion of patients who had
complete resolution of the retinal fluid compartments of
SRF, CIRF, and NIRF on OCT during REACH stage 3 was
also evaluated. An ‘‘all dry’’ retina status was defined as
complete resolution of all 3 compartments of fluid (any
compartment with missing data was considered to be dry).
SD-OCT images showing the resolution of retinal fluid
compartments in a patient in the abicipar 2mg arm are
presented in Supplementary Fig. S3.
All patients in each treatment arm had at least 1 form of
retinal fluid present at baseline. At weeks 4 and 8, abicipar
1mg and 2mg resolved fluid accumulation more effectively
than ranibizumab 0.5mg (Fig. 4). At week 12, the proportion
of patients with an ‘‘all dry’’ status among those who re-
mained in REACH stage 3 and had not been rescued (unless
rescued with ranibizumab in the ranibizumab group) was
70.8% and 77.3% in the abicipar 1mg and 2mg arms com-
pared with 50.0% in the ranibizumab 0.5mg arm. At week 16
(8 weeks after the last abicipar injection), the proportion of
patients with complete resolution of these fluid compartments
was 47.4% and 47.4% in the abicipar 1mg and 2mg arms
compared with 18.8% in the ranibizumab arm (4 weeks after
intravitreal ranibizumab). At the end of REACH stage 3
(week 20, 12 weeks after the last abicipar injection and 4
weeks after the last intravitreal ranibizumab injection), the
proportion of patients with complete resolution of fluid was
50.0%, 46.2%, and 42.9% in the abicipar 1mg, abicipar 2mg,
and ranibizumab 0.5mg arms, respectively. Similar results
were obtained in a supplementary analysis that used all ob-
served data in all treatment arms and included data from
patients after escape to SoC (Supplementary Fig. S4).
Fluorescein angiography showed decreases in the mean
area of CNV at week 20, with no significant differences
between the abicipar groups and the ranibizumab group.
Pharmacokinetics and immunogenicity
To evaluate the potential for abicipar to inhibit systemic
VEGF action and elicit production of anti-abicipar/pegol
antibodies, pharmacokinetic and immunogenicity testing
was conducted. The concentration of free abicipar was
measurable in serum samples collected on day 3 in both
abicipar treatment arms (mean– standard deviation con-
centration of 0.55 – 0.35 nM in the abicipar 1mg arm and
1.05 – 0.60 nM in the abicipar 2mg arm), as well as in serum
FIG. 3. Change from baseline in CRT (mm) in the modi-
fied intent-to-treat population of patients treated with abi-
cipar 1mg (light green lines and squares; n = 25), abicipar
2mg (dark green lines and squares; n = 23), or ranibizumab
0.5mg (orange lines and circles; n = 16). Data shown are
least-squares means – standard errors from the mixed-effects
model for repeated measures. There were no statistically
significant differences between abicipar 1mg or 2mg and
ranibizumab 0.5mg in change in CRT from baseline. Green
and orange arrows indicate when the 3 abicipar injections or
5 ranibizumab injections were administered. Mean – stan-
dard error of the mean CRT at baseline for the abicipar
1mg, abicipar 2mg, and ranibizumab 0.5mg arms was
526 – 33, 466– 26, and 463– 24mm, respectively. B, base-
line. CRT, central retinal thickness.
FIG. 4. Proportion (%) of patients in the modified intent-to-
treat population achieving resolution of the 3 fluid compart-
ments of subretinal fluid, intraretinal cyst, and intraretinal
fluid (an ‘‘all dry’’ retina) after treatment with abicipar 1mg
(light green bars; n= 25), abicipar 2mg (dark green bars;
n= 23), or ranibizumab 0.5mg (orange bars; n= 16). Pro-
portions are calculated for patients with data available who
had not been rescued (unless rescued with ranibizumab in the
ranibizumab group). Green and orange arrows indicate when
the 3 abicipar or 5 ranibizumab injections were administered.
P=0.017 versus ranibizumab; P=0.049 versus ranibizumab,
P=0.003 versus ranibizumab.
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samples collected at week 1 in the abicipar 2mg arm (mean
concentration of 0.43 – 0.33 nM). At all other timepoints,
serum concentrations of free abicipar were below the limit
of quantitation (0.3 nM) in all samples. Pharmacokinetic
parameters such as t1/2 could not be calculated because of
the limited number of timepoints at which concentrations of
abicipar could be determined.
Anti-abicipar antibodies were detectable in blood samples
from 14/25 (56.0%) patients in the abicipar 1mg arm and in
3/23 (13.0%) patients in the abicipar 2mg arm. Antibodies
directed to the pegol portion of the protein (anti-PEG anti-
bodies) were detectable in 2/25 (8.0%) patients in the abi-
cipar 1mg arm after the first injection of abicipar 1mg. No
patients in the abicipar 2mg arm had anti-PEG antibodies at
any timepoint, and all patients in the abicipar 1mg arm were
negative for anti-PEG antibodies at their last visit with
immunogenicity data, indicating a transient antibody re-
sponse against the pegol moiety of abicipar. A relationship
between the presence of anti-abicipar antibodies and safety
and/or efficacy data could not be established.
Safety outcomes
The overall incidence of AEs in REACH stage 3 was 15/25
in the abicipar 1mg arm, 10/23 in the abicipar 2mg arm, and
9/16 in the ranibizumab 0.5mg arm. Most events were mild
or moderate in severity. Treatment-related AEs were reported
in 10/25, 4/23, and 3/16 of patients in the abicipar 1mg,
abicipar 2mg, and ranibizumab 0.5mg arms, respectively.
With the exception of an AE reported as iron deficiency in the
abicipar 2mg arm, all of these AEs were ocular. The most
common ocular AEs (reported in ‡2 patients in any treatment
arm) were vitreous floaters, vitreous detachment, retinal
hemorrhage, eye pain, conjunctival hemorrhage, and macular
scar (Table 2). Both events of macular scar in the ranibizu-
mab arm and 4 events of retinal hemorrhage (2 in the abicipar
1mg arm and 2 in the ranibizumab arm) were reported to be
unrelated to the study drug or injection. An additional event
of retinal hemorrhage in the abicipar 1mg arm was reported
to be related to the injection. No deaths or other serious AEs
were reported in any treatment arm.
Intraocular inflammation (IOI) AEs were reported in 5
patients (3 [12.0%] in the abicipar 1mg arm, 2 [8.7%] in the
abicipar 2mg arm, and none in the ranibizumab arm). In the
abicipar 1mg arm, these AEs included iritis (reported as
iritis; moderate; after the third injection), uveitis (reported as
panuveitis; moderate; after the second injection), and vitritis
(reported as vitritis; severe; after the third injection). In the
abicipar 2mg arm, these AEs included iritis (reported as
iritis; mild; after the third injection) and choroiditis (re-
ported as posterior uveitis; moderate; after the second in-
jection). The patient with vitritis did not receive any
treatment and the AE resolved; the other 4 patients with IOI
received topical corticosteroid treatment, and 2 of these
patients also received 1 week of oral corticosteroid treat-
ment. The patient in the abicipar 2mg arm with choroiditis
discontinued from the study because of the AE; the chor-
oiditis resolved without sequelae after treatment with a
topical corticosteroid. All AEs of IOI resolved without se-
quelae within 26–84 days, and none was associated with a
sustained loss in vision (Table 3).
No Antiplatelet Trialists Collaboration arterial thrombo-
embolic events (APTC ATEs; including nonfatal myocardial
infarction, nonfatal stroke, vascular death, and death of un-
known cause)18 were reported in REACH stage 3. The only
systemic AE potentially related to systemic VEGF inhibition
reported in REACH stage 3 was hypertension. An AE of hy-
pertension was reported in 1 patient in the abicipar 2mg arm
and 1 patient in the ranibizumab 0.5mg arm, and both were
deemed not related to study treatment by the investigator. No
hypertension AEs were reported in the abicipar 1mg arm.
Overall, 19/25 (76.0%) patients in the abicipar 1.0mg
arm, 15/23 (65.2%) patients in the abicipar 2.0mg arm, and 10/
16 (62.5%) patients in the ranibizumab arm had a ‡1-grade
increase from baseline in the severity of any biomicroscopy or
ophthalmoscopy finding during the study. A ‡1-grade increase
in the severity of detachment of macular RPE (no findings at
screening and positive findings during the study) was reported
in 2 (8.0%) patients in the abicipar 1mg arm and no patients in
either the abicipar 2mg arm or the ranibizumab arm.
Table 2. Adverse Events in the Study Eye
in the REACH Stage 3 Study
AEa
Number (%) of patients
Abicipar
1mg
(n = 25)
Abicipar
2mg
(n = 23)
Ranibizumab
0.5mg
(n = 16)
Overall incidenceb 11 (44.0) 7 (30.4) 5 (31.3)
Vitreous floaters 3 (12.0) 1 (4.3) 1 (6.3)
Vitreous detachment 2 (8.0) 2 (8.7) 0
Retinal hemorrhage 3 (12.0) 0 2 (12.5)
Eye pain 1 (4.0) 2 (8.7) 1 (6.3)
Conjunctival
hemorrhage
2 (8.0) 0 0
Macular scar 0 0 2 (12.5)
aAll AEs reported in the study eye for 2 or more patients in any
treatment arm are listed.
bPatients with 1 or more AEs in the study eye.
AE, adverse event.
Table 3. Visual Outcomes After Intraocular Inflammation Adverse Events
Intraocular inflammation
AE (MedDRA preferred term) Treatment arm
Worst change from baseline
BCVA after AE (letters)
BCVA change from baseline at
escape to SoC or study exit (letters)
Iritis Abicipar 1mg -5 -1
Uveitis Abicipar 1mg -2 +4
Vitritis Abicipar 1mg +14 +22
Iritis Abicipar 2mg NA +2
Choroiditis Abicipar 2mg -19 +7
AE, adverse event; BCVA, best-corrected visual acuity; MedDRA, medical dictionary for regulatory activities; NA, not available; SoC,
standard of care.
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Discussion
Sudden vision loss in advanced AMD is attributed in
large part to nAMD, and anti-VEGF agents such as ranibi-
zumab have changed clinical practice for the treatment of
this disease.1 In registration studies of anti-VEGF treatment
in nAMD,4,5,17 vision was improved or stabilized in more
than 90% of patients, and the effects on vision were asso-
ciated with significantly improved vision-related quality of
life.19,20 Accordingly, intravitreal injections of anti-VEGF
drugs have become the mainstay of current treatment for
nAMD.1 A drawback to this treatment, however, is the need
for frequent intravitreal injections. In clinical trials, monthly
injections of anti-VEGF therapies have provided the most
robust efficacy outcomes.21 Therefore, there is currently an
unmet medical need for a therapy that can maintain maximal
efficacy while requiring less frequent injections. Not only
would such a therapy remove a significant treatment burden
on patients and their healthcare providers, but it would also
decrease the risk of complications associated with intravitreal
injections such as endophthalmitis, retinal detachment, and
elevated intraocular pressure. The data from REACH stage 3
suggest that, in comparison to ranibizumab, abicipar elicits
similar visual acuity gains with a reduced number of injec-
tions (3 vs. 5 in this short-duration study). The data also
demonstrate that for many patients, effects on BCVA are
maintained 12 weeks after the last injection of abicipar,
suggesting greater duration of effect, and indicating that
abicipar could provide similar efficacy compared with rani-
bizumab, but with reduced burden of visits for patients and
healthcare providers.
In REACH stage 3, abicipar induced rapid increases in
BCVA from baseline, achieving the maximal effect by week
8, after 2 intravitreal injections, and demonstrating sustained
efficacy at week 16, the timepoint for the primary endpoint.
It is important to note that week 16 corresponded to 8 weeks
after the last abicipar injection. At week 20, mean change
from baseline BCVA was +8.2 and +10.0 letters with abi-
cipar 1mg and 2mg, respectively, compared with +5.3 let-
ters for ranibizumab. These data suggest that an 8-week or
12-week dosing interval for abicipar may be feasible to
sustain efficacy outcomes.
Differences in the selection criteria for patient popula-
tions of this study and the ranibizumab registration studies
(e.g., allowed lesion size, and inclusion or exclusion of
patients with RAP, large pigment epithelial detachment, and
previous treatment) can make it difficult to compare results
between studies. In the ranibizumab registration studies, the
distribution of lesion types in the ranibizumab 0.5mg
treatment arm was 96% predominantly classic, 4% mini-
mally classic, and 0% occult in the ANCHOR study4 and
0% predominantly classic, 38% minimally classic, and 62%
occult in the MARINA study.5 In the ranibizumab 0.5mg
treatment arm in REACH stage 3, the proportion of patients
with predominantly classic lesions was 19% and the pro-
portion of patients with occult lesions was 81%; due to the
similarities in the distribution of lesion type, the MARINA
study may be the more relevant comparator study for the
ranibizumab outcomes in REACH stage 3. Mean BCVA
change from baseline with monthly injections of ranibizu-
mab was +5.6 and +5.3 letters at weeks 16 and 20 in
REACH stage 3, similar to the +6.1 and +6.2 letters seen in
MARINA for ranibizumab.
Evaluation of retinal anatomy using OCT suggested that
abicipar effects were maintained through 12 weeks after the
final abicipar administration, with CRT values for abicipar
1 and 2mg that were comparable to those obtained with
ranibizumab administered monthly. However, change in
CRT is a relatively insensitive measure of the effect of anti-
VEGF treatment on exudation, and it is not well correlated
with recovery of vision in nAMD.22 Anatomical abnor-
malities in addition to CNV lesions and exudation, such as
photoreceptor and RPE cell dropout and fibrosis, also con-
tribute to abnormal retinal thickness. These would not re-
solve with anti-VEGF treatment.
SD-OCT visualization of the presence or absence of specific
fluid compartments that form in patients with nAMD, in-
cluding SRF, CIRF, NIRF, and pigment epithelial detach-
ments, avoids the limitations of CRT measurements.23,24
Therapeutic effects of treatment may be reflected by changes
in these fluid compartments, and there is ongoing discussion of
the importance of these anatomical changes.23,25,26 The pres-
ence of CIRF has been significantly associated with poor vi-
sual recovery.27,28 Not all patients have all 3 of these fluid
compartments, but the presence of SRF, NIRF, and CIRF is
commonly used in clinical retina practice to guide anti-VEGF
treatment. Therefore, the complete resolution of these 3 retinal
fluid compartments may be a relatively sensitive assessment
for comparing different therapies and dosing frequencies. This
was evaluated as an exploratory endpoint in REACH stage 3,
where resolution of all 3 fluid compartments appeared to
correlate with improvements in BCVA. The proportion of
patients with an ‘‘all dry’’ status was significantly higher in the
abicipar 2mg arm than in the ranibizumab arm at week 4 and
significantly higher in both abicipar arms than in the ranibi-
zumab arm at week 8, suggesting that abicipar may be more
effective than ranibizumab in achieving an ‘‘all dry’’ retina
status during the early phase of treatment. Throughout the
remainder of REACH stage 3, the proportion of patients with
an ‘‘all dry’’ status was similar in the abicipar arms compared
with the ranibizumab arm, despite the greater frequency of
injections administered in the ranibizumab arm.
With respect to safety, abicipar was well tolerated, as the
overall incidence of AEs in REACH stage 3 for abicipar (1
and 2mg) was comparable to that for ranibizumab 0.5mg,
and most events were mild or moderate in severity. No se-
rious AEs of IOI were reported, and only 1 AE of IOI re-
sulted in discontinuation from REACH stage 3. In all cases,
AEs of IOI resolved without sequelae. The etiology of IOI
in abicipar-treated patients and the manufacturing process
used for abicipar will continue to be investigated. Overall,
the rate of IOI with abicipar in REACH stage 3 was similar
to that reported with ranibizumab in early clinical trials for
the treatment of nAMD.4,5
In addition to ocular AEs, systemic AEs were also
monitored, particularly those potentially related to systemic
VEGF inhibition; these included hypertension. One AE of
hypertension (1/23; 4.3%) was reported in the abicipar 2mg
arm. Evaluation of systemic levels of abicipar suggested no
association with the reported hypertensive event. One AE of
hypertension was also reported in the ranibizumab arm (1/
16; 6.3%). Of note, systemic concentrations of ranibizumab
have been demonstrated to be low, with little effect on
plasma VEGF concentrations.29
Weaknesses of REACH stage 3 include the limited
number of enrolled patients and the relatively short duration
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of the study. Because the study protocol had broad criteria
for active disease at or after week 12, a substantial number
of patients in each treatment arm were prescribed escape
therapy. Strengths of this study include the exploration of
the durability of abicipar effects and the evaluation of
complete resolution of retinal fluid compartments, in addi-
tion to CRT and BCVA, as efficacy measures.
In conclusion, abicipar provided marked improvements in
BCVA and CRT in REACH stage 3. A dosing regimen of 3
initial monthly injections provided long-lasting, beneficial
treatment effects in most patients for 8–12 weeks after the
last (third) abicipar injection. These effects were similar to
those of a fixed monthly ranibizumab 0.5-mg regimen. In
other words, similar BCVA and CRT improvement was
achieved with a total of 3 abicipar injections versus 5 ra-
nibizumab injections in REACH stage 3. Abicipar 1mg and
2mg performed as well or better than ranibizumab 0.5mg in
providing patients with an ‘‘all dry’’ retina (no NIRF, CIRF,
or SRF), and as with the primary and secondary outcomes, it
did so with a reduced number of injections. Overall, abicipar
was well tolerated; the incidence of treatment-related AEs
was comparable to ranibizumab. No serious AEs were re-
ported. IOI was observed in the abicipar-treated arms at
rates similar to those reported in the registration studies for
ranibizumab. IOI AEs responded well to treatment and re-
solved without sequelae; and in 1 patient, the IOI AE re-
solved without any treatment (Table 3). With respect to
systemic AEs, no APTC ATEs were observed.
Overall, the REACH stage 3 data suggest that abicipar
could achieve similar efficacy to monthly injections of ra-
nibizumab 0.5mg, but with a reduced number of injections
and dosing intervals of 8 or 12 weeks, consistent with
greater durability of action. These data represent the foun-
dation for larger and longer-duration studies with abicipar to
evaluate its potential as an effective therapy for nAMD.
Global phase 3 clinical trials of abicipar in patients with
nAMD are ongoing (NCT02462486, NCT02462928).
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